Nabi Biopharmaceuticals

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Nabi Biopharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 12 completed later-stage tilt top decile by trial count

Nabi Biopharmaceuticals: 13 sponsored US clinical trials, none currently recruiting.

Nabi Biopharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 11 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Smoking Cessation, with 2 trials.

Top-decile sponsor footprint

Nabi Biopharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 71/100

12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

COMPLETED Phase 3

A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers

NCT01375933
COMPLETED

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

NCT01304810
COMPLETED Phase 3

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

NCT01178346
COMPLETED Phase 3

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

NCT01102114
COMPLETED Phase 3

NicVAX/Placebo as an Aid for Smoking Cessation

NCT00836199
COMPLETED Phase 1

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

NCT00598325
TERMINATED Phase 3

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

NCT00130260
COMPLETED Phase 3

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

NCT00211978
COMPLETED Phase 3

Evaluation of Consistency of StaphVAX Manufacturing Lots

NCT00211991
COMPLETED Phase 3

Evaluation of Manufacturing Lot of StaphVAX

NCT00211900
COMPLETED Phase 4

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

NCT00211939
COMPLETED Phase 3

StaphVAX Immunogenicity in Orthopedic Implant Patients

NCT00211926
COMPLETED Phase 3

StaphVAX in Cardiovascular Surgery Patients

NCT00211913

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 10
Phase 4 1

Therapeutic Areas

Smoking Cessation 2
Hyperparathyroidism, Secondary 1
Calcinosis 1
Arteriosclerosis 1
Nicotine Dependence 1

How the Nabi Biopharmaceuticals archive is shaped

13 indexed studies, none listed as recruiting (0% open); 12 completed (92%).

Phase mix: 11 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Smoking Cessation (2 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nabi Biopharmaceuticals: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Nabi Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share Nabi BiopharmaceuticalsAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Nabi Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nabi Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nabi Biopharmaceuticals page

13 registered trials is a research-attention snapshot, not an endorsement of Nabi Biopharmaceuticals or any single study.

  • None of Nabi Biopharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Smoking Cessation is the condition Nabi Biopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Smoking Cessation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Nabi Biopharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.